Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Surrozen, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SRZN
Nasdaq
2834
www.surrozen.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Surrozen, Inc.
Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation
- Jan 22nd, 2025 11:08 am
Surrozen to Present at Upcoming Healthcare Investor Conferences
- Nov 6th, 2024 9:30 pm
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
- Nov 6th, 2024 2:00 pm
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
- Nov 4th, 2024 1:30 pm
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
- Sep 24th, 2024 12:30 pm
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky
- Aug 15th, 2024 10:21 am
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
- Aug 12th, 2024 8:05 pm
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
- Jun 12th, 2024 12:30 pm
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
- Jun 10th, 2024 12:30 pm
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
- Jun 4th, 2024 12:30 pm
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- May 9th, 2024 12:30 pm
Surrozen Provides First Quarter 2024 Financial Results and Business Update
- May 8th, 2024 8:05 pm
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
- Apr 3rd, 2024 12:40 pm
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
- Apr 1st, 2024 12:30 pm
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
- Apr 1st, 2024 12:30 pm
Scroll